Search | Clinical Trials Finder

Conditions: Non Small Cell Lung Cancer
Interventions: AZD6244, docetaxel, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: YPL-001 80 mg, YPL-001 160 mg, Placebo; Drug
Lead sponsor: Yungjin Pharm. Co., Ltd.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more

Conditions: Lennox Gastaut Syndrome
Interventions: ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more

Conditions: Parkinson's Disease, Dyskinesia
Interventions: Sarizotan, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 30 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 32
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more

Conditions: HCV Infection
Interventions: VCH 916, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: TRx0237, Placebo; Drug
Lead sponsor: TauRx Therapeutics Ltd; Industry
Eligibility: Up to 79 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more

Conditions: Covid19, SARS-CoV Infection
Interventions: Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo; Dietary Supplement
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions: AZD4901 (oral), Placebo to match AZD4901; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Springfield, Missouri

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: National City, California

Conditions: Bipolar Disorder
Interventions: Riluzole, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: Renal Insufficiency, Chronic
Interventions: 6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo; Drug · Other · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Psoriasis
Interventions: Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more

Conditions: Cirrhosis
Interventions: Transcutaneous Electrical Acustimulation (TEA), Sham Transcutaneous Electrical Acustimulation (TEA); Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Conditions: Smoking Cessation
Interventions: Varenicline Tartrate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions: Instilled T3, Placebo Therapy; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Barrett's Esophagus
Interventions: Dexlansoprazole, Dexlansoprazole Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Jacksonville, Florida • Chapel Hill, North Carolina • Knoxville, Tennessee

Conditions: Smoking Cessation
Interventions: APD356-lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 31
States / cities: Encino, California • Escondido, California • Los Alamitos, California + 27 more

Conditions: CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions: Fenfluramine, Placebo; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Huntington Disease
Interventions: ACR16, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more

Conditions: Chronic Kidney Diseases, Endothelial Dysfunction
Interventions: Resveratrol, Placebo; Dietary Supplement · Other
Lead sponsor: Diana Jalal; Other
Eligibility: 45 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Tobacco Dependence
Interventions: varenicline, placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Sudden Cardiac Death, Ventricular Arrythmias
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Wausau, Wisconsin

Search by objective public record fields.

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

Riluzole to Treat Depression in Bipolar Disorder

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Neurovascular Transduction During Exercise in Chronic Kidney Disease

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

Resveratrol and Vascular Function in CKD

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction